What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-05-14 compared with 2020-11-09 · 33 added, 45 removed, 140 unchanged (36% of the section changed)

OTHER INFORMATION

On October 20, 2020, the Company entered into

a Distribution Agreement with Adial Pharmaceuticals, Inc.

(“Adial”) (the “Adial Agreement”).

the Adial Agreement, the Company was appointed as a non-exclusive sub-distributor of Adial’s SARS-CoV-2 antibody tests and

antigen tests and other medical devices and equipment worldwide.

Stilley, a director of the Company as well as a member of

the Nominating and Corporate Governance Committee and Audit Committee, is the Chief Executive Officer and a director of Adial.

On August 17, 2020,

the Company entered into a Commercialization Partnership Agreement with Cellex, Inc.

(“Cellex”), which was dated August

10, 2020 (the “Cellex Agreement”).

Pursuant to the Cellex Agreement, the Company was granted a right to promote, market,

transfer, distribute, and/or sell Cellex’s qSARS-COV-2 IgG/IgM Rapid Test Kit and Kit Control on a non-exclusive basis.

Cellex Agreement provides that the Company may purchase the products at a set per unit price and, in the event of bulk sales or

tender offers, the Company may receive a commission.

On December 13,

2019, the Company entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies

LLC, as sales agent (“Jefferies”), pursuant to which the Company may offer and sell, from time to time, through Jefferies,

shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $20.0 million.

2020, the date on which the Company filed its Annual Report on Form 10-K for the fiscal year ended December 31,

2019, the Company’s registration statement became subject to the offering limits set forth in General Instruction I.B.6 of

During the nine months ended September 30, 2020, Jefferies sold an aggregate of 3,468,315 shares of common

stock at an average price of $1.80 per share to investors.

The Company recorded net proceeds of $5,875,755, net of commission and

other offering costs of $357,923.

From October 1, 2020 to November 9, 2020, Jefferies sold an aggregate of 41,909 shares of common

stock at an average price of $1.55 per share to investors.

The Company received net cash proceeds of $63,197, net of commission

paid to sales agent of $1,955.

The following exhibits are filed as part of, or incorporated

by reference into, this Quarterly Report on Form 10-Q.

December 13, 2019, the Company entered into an Open Market Sale Agreement SM (the

“Sales Agreement”) with Jefferies LLC, as sales agent (“Jefferies”), pursuant to which the Company may offer

and sell, from time to time, through Jefferies, shares of its common stock, par value $0.0001 per share, having an aggregate offering

price of up to $20.0 million.

On April 6, 2020, the date on which the Company filed its Annual Report on Form 10-K for the

fiscal year ended December 31, 2019, the Company’s registration statement became subject to the offering limits set forth

in General Instruction I.B.6 of Form S-3.

From December 13, 2019 through May 12, 2021, Jefferies sold an aggregate of 5,900,275

shares of common stock at an average price of $1.62 per share to investors.

The Company received net cash proceeds of $9,272,463, net

of commission paid to sales agent of $286,777.

following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Open Market Sale AgreementSM, dated as of December 13, 2019, by and between Avalon GloboCare Corp.

130 unchanged sentences

List of Subsidiaries (incorporated by reference to Exhibit 21.1 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 20, 2018)

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act

Certification of Chief

Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act

Certification of Chief

Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act

Certification of Chief

Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act

XBRL INSTANCE DOCUMENT

XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION

SCHEMA DOCUMENT

XBRL TAXONOMY EXTENSION

CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION

DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION

LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION

PRESENTATION LINKBASE DOCUMENT

Filed herewith

Management contract or compensatory plan or arrangement.

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Management contract or

compensatory plan or arrangement.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

AVALON GLOBOCARE CORP.

November 9, 2020

Chief Executive Officer, President and Director (Principal Executive Officer)

November 9, 2020

Chief Executive Officer, President and Director (Principal Executive

/s/ Luisa Ingargiola

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information